157 related articles for article (PubMed ID: 26438520)
1. Serum and plasma 5-hydroxyindoleacetic acid as an alternative to 24-h urine 5-hydroxyindoleacetic acid measurement.
Adaway JE; Dobson R; Walsh J; Cuthbertson DJ; Monaghan PJ; Trainer PJ; Valle JW; Keevil BG
Ann Clin Biochem; 2016 Sep; 53(Pt 5):554-60. PubMed ID: 26438520
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of whole blood serotonin and plasma and urine 5-hydroxyindole acetic acid in diagnosis of carcinoid disease.
Carling RS; Degg TJ; Allen KR; Bax ND; Barth JH
Ann Clin Biochem; 2002 Nov; 39(Pt 6):577-82. PubMed ID: 12564839
[TBL] [Abstract][Full Text] [Related]
3. Measurement of plasma 5-hydroxyindoleacetic acid in carcinoid disease: an alternative to 24-h urine collections?
Degg TJ; Allen KR; Barth JH
Ann Clin Biochem; 2000 Sep; 37 ( Pt 5)():724-6. PubMed ID: 11026528
[No Abstract] [Full Text] [Related]
4. Plasma or serum 5-hydroxyindoleacetic acid can be used interchangeably in patients with neuroendocrine tumours.
Ewang-Emukowhate M; Subramaniam K; Lam F; Hayes A; Mandair D; Toumpanakis C; Grossman A; Nair D; Caplin M
Scand J Clin Lab Invest; 2023 Dec; 83(8):576-581. PubMed ID: 38112030
[TBL] [Abstract][Full Text] [Related]
5. Analytical and preanalytical validation of a new mass spectrometric serum 5-hydroxyindoleacetic acid assay as neuroendocrine tumor marker.
Tohmola N; Itkonen O; Sane T; Markkanen H; Joenväärä S; Renkonen R; Hämäläinen E
Clin Chim Acta; 2014 Jan; 428():38-43. PubMed ID: 24211728
[TBL] [Abstract][Full Text] [Related]
6. Determination of the optimal echocardiographic scoring system to quantify carcinoid heart disease.
Dobson R; Cuthbertson DJ; Jones J; Valle JW; Keevil B; Chadwick C; Poston GP; Burgess MI
Neuroendocrinology; 2014; 99(2):85-93. PubMed ID: 24603343
[TBL] [Abstract][Full Text] [Related]
7. The association of a panel of biomarkers with the presence and severity of carcinoid heart disease: a cross-sectional study.
Dobson R; Burgess MI; Banks M; Pritchard DM; Vora J; Valle JW; Wong C; Chadwick C; George K; Keevil B; Adaway J; Ardill JE; Anthoney A; Hofmann U; Poston GJ; Cuthbertson DJ
PLoS One; 2013; 8(9):e73679. PubMed ID: 24069222
[TBL] [Abstract][Full Text] [Related]
8. Measurement of plasma 5-hydroxyindole acetic acid by liquid chromatography tandem mass spectrometry--comparison with HPLC methodology.
Miller AG; Brown H; Degg T; Allen K; Keevil BG
J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Mar; 878(7-8):695-9. PubMed ID: 20117968
[TBL] [Abstract][Full Text] [Related]
9. The clinical and laboratory correlates of an increased urinary 5-hydroxyindoleacetic acid.
Tormey WP; FitzGerald RJ
Postgrad Med J; 1995 Sep; 71(839):542-5. PubMed ID: 7479466
[TBL] [Abstract][Full Text] [Related]
10. Discriminating capacity of indole markers in the diagnosis of carcinoid tumors.
Meijer WG; Kema IP; Volmer M; Willemse PH; de Vries EG
Clin Chem; 2000 Oct; 46(10):1588-96. PubMed ID: 11017936
[TBL] [Abstract][Full Text] [Related]
11. HPLC-mass spectrometry method for quantitative detection of neuroendocrine tumor markers: vanillylmandelic acid, homovanillic acid and 5-hydroxyindoleacetic acid.
Lionetto L; Lostia AM; Stigliano A; Cardelli P; Simmaco M
Clin Chim Acta; 2008 Dec; 398(1-2):53-6. PubMed ID: 18760269
[TBL] [Abstract][Full Text] [Related]
12. Urinary free cortisol excretion in patients with hyperserotoninaemia from the carcinoid syndrome.
Feldman JM
Clin Endocrinol (Oxf); 1979 Nov; 11(5):541-8. PubMed ID: 316372
[TBL] [Abstract][Full Text] [Related]
13. Carcinoid tumors of the pancreas. Status report based on two cases and review of the world's literature.
Mao C; el Attar A; Domenico DR; Kim K; Howard JM
Int J Pancreatol; 1998 Apr; 23(2):153-64. PubMed ID: 9629513
[TBL] [Abstract][Full Text] [Related]
14. Carcinoid Heart Disease: Prognostic Value of 5-Hydroxyindoleacetic Acid Levels and Impact on Survival: A Systematic Literature Review.
Buchanan-Hughes A; Pashley A; Feuilly M; Marteau F; Pritchard DM; Singh S
Neuroendocrinology; 2021; 111(1-2):1-15. PubMed ID: 32097914
[TBL] [Abstract][Full Text] [Related]
15. [Carcinoid: diagnosis and therapy].
May B
Dtsch Med Wochenschr; 1975 Oct; 100(42):2163-5. PubMed ID: 1100341
[No Abstract] [Full Text] [Related]
16. Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors.
Feldman JM; O'Dorisio TM
Am J Med; 1986 Dec; 81(6B):41-8. PubMed ID: 2432780
[TBL] [Abstract][Full Text] [Related]
17. Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours.
Turner GB; Johnston BT; McCance DR; McGinty A; Watson RG; Patterson CC; Ardill JE
Gut; 2006 Nov; 55(11):1586-91. PubMed ID: 16556667
[TBL] [Abstract][Full Text] [Related]
18. A single fasting plasma 5-HIAA value correlates with 24-hour urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors (NETs).
Tellez MR; Mamikunian G; O'Dorisio TM; Vinik AI; Woltering EA
Pancreas; 2013 Apr; 42(3):405-10. PubMed ID: 23160483
[TBL] [Abstract][Full Text] [Related]
19. Immunoreactive tachykinins in 24-h collections of urine from patients with carcinoid tumours: characterization and correlation with plasma concentrations.
Bergstrom M; Theodorsson E; Norheim I; Oberg K
Scand J Clin Lab Invest; 1995 Dec; 55(8):679-89. PubMed ID: 8903838
[TBL] [Abstract][Full Text] [Related]
20. Serotonin metabolism in patients with carcinoid tumors: incidence of 5-hydroxytryptophan-secreting tumors.
Feldman JM
Gastroenterology; 1978 Dec; 75(6):1109-14. PubMed ID: 309417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
